First report 25 Mar 2026•Latest report 25 Mar 2026
Recipient record
Reports, concerns and published responses
Private and voluntary organisations · Private limited company. This page brings together reports naming this recipient and response statements clearly connected to concerns raised in those reports.
Reports
1
Naming this recipient
Published responses
100%
Found for named reports
Concerns addressed
1
Across all linked responses
Stated actions
3
Described in responses
Reports over time
Reports over time
Reports naming this recipient by issue year.
Evidence profile
Report topics
Share of this recipient’s reports compared with all other recipients.
100%published responses found
3stated actions described
Topic comparisons are not available in the current evidence snapshot.
Concerns and recipient responses
Statements from Haleon UK Trading Limited linked to the concerns in each report. Select any concern, action or position to view the source wording.
Inner West London
Concerns raised7
Failure to routinely seize feeding bottles and equipment pending toxicology results
Insufficient police consideration of poisoning in unexpected child deaths
Warning information for chlorpheniramine-containing products omitting their association with sudden unexpected death in children
Perfunctory scene examinations in child death investigations
Police training and guidelines requiring updating
A person who illicitly administered chlorpheniramine to a child continuing to work as a nanny
Absence of a national regulation system for nannies
Responses linked to these concerns
Each statement is shown once, even when linked to more than one concern.
Respondent positions A position is what this recipient says about the concern when it does not describe a specific action.3
Position
The Medicines and Healthcare products Regulatory Agency is the appropriate addressee for requests to change product labelling.
Redirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
Position
The specific product administered has not been established, so Haleon’s involvement and product-specific risk cannot be confirmed.
Disputes the concernThe respondent disagreed with part of the concern or the basis for it.
Position
Existing Piriton labelling provides clear age and dosing instructions and complies with applicable UK medicines regulations and guidance.
Existing arrangements considered sufficientThe respondent said that existing arrangements were sufficient, so no further action was needed.